Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe’s Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board
October 31 2022 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT), which is continuing to expand
its Key Opinion Leader (KOL) support network, today announced that
Thierry Jacques De Baère, MD, PhD, is joining the Company’s
Scientific Advisory Board (SAB). Dr. De Baère is head of the
Interventional Radiology Unit at Institut Gustave Roussy Cancer
Center in Villejuif, France, the largest cancer center in Europe.
The Company’s SAB now includes 11 members from the U.S., Europe and
Israel, who support the rising momentum for the Company’s LIBERTY®
Robotic System.
“The LIBERTY® Robotic System has made
significant progress in recent weeks, due in part to the incredible
support we have received from our dedicated Scientific Advisory
Board, which is made up of renowned global leaders in the medical
robotics and endovascular spaces,” commented Harel Gadot, CEO,
President, and Chairman. “Dr. De Baère is a leader in the
endovascular space, who realized the potential of the LIBERTY
Robotic System after his own personal experience. We are certain
he, along with many others that are currently evaluating the
system, will be valued contributors and play an important role
through our regulatory process and expected commercialization in
the global markets.”
“I recently had the chance to use the LIBERTY
Robotic System in a pre-clinical setting, and as someone who does
many interventional oncology procedures, I was impressed with how
easy the system was to set up and how effortlessly I could get to
my target,” commented Dr. De Baère. “From my experience, it is
reassuring that the LIBERTY Robotic System appears to be reliable
and predictable. I am happy to join the Microbot team, and look
forward to helping them bring LIBERTY to market so we can
potentially improve the lives of more patients.”
Dr. De Baère is the author of 280 peer-reviewed
articles and over 350 scientific communications, reviewer for many
cancer and interventional radiology journals, and section chief
editor for the oncology section in CardioVascular and
Interventional Radiology (CVIR) Journal. He is also a member of The
Cardiovascular and Interventional Radiological Society of Europe
(CIRSE) and the European Society for Medical Oncology (ESMO).
Additionally, Dr. De Baère is principal investigator of several
international studies on ablation, intraarterial therapies,
combined therapies and other innovative locoregional treatments and
recently used the LIBERTY system in a pre-clinical setting.
The LIBERTY Robotic System is the world’s first
fully disposable robotic system for use in endovascular
(neurovascular, cardiovascular and peripheral) procedures. The
LIBERTY Robotic system features a unique compact design with the
capability to be operated remotely, reduce radiation exposure and
physical strain to the physician. With the planned integration of
the recently acquired FDA-cleared NovaCross™ family of
microcatheters and the One & Done™ technology, the Company
expects to standardize the way endovascular procedures are
conducted, while eliminating barriers to access and increasing the
adoption rate of robotics in the endovascular space.
For a complete list and background on the
members of the SAB, please use this link About – Microbot
Medical
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY and the One & Done™
technologies, the outcome of its studies to evaluate LIBERTY, the
One & Done™ technologies and other existing and future
technologies, any failure or inability to recruit physicians and
clinicians to serve as primary investigators to conduct regulatory
studies which could adversely affect or delay such studies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael PolyviouEVC Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024